A Phase I Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluate the safety of chemotherapy with the drug decitabine combined with rapamycin to determine the highest dose of rapamycin that can be given in combination with decitabine.
6 months
Yes
Jane Liesveld, MD
Principal Investigator
University of Rochester
United States: Institutional Review Board
26037
NCT00861874
January 2010
Name | Location |
---|---|
University of Rochester | Rochester, New York 14642 |